Abstract 568P
Background
Testing for DNA mismatch repair deficiency (MMRd) is recommended for all colorectal cancers (CRC). Automation of this would facilitate precision medicine, particularly if it provided information on likely aetiology.
Methods
We developed AIMMer, an AI-based method for determination of MMR protein expression at single cell level from IHC-stained routine pathology samples. We applied it to over 2,000 cases from the SCOT clinical trial, which compared 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy (mFOLFOX6 or CAPOX) for stage II/III CRC. AIMMer performance was evaluated against ground truth established by blinded review by two expert pathologists, and MMRd prognostic and predictive value was determined by Cox proportional hazards models.
Results
Benchmarking of AIMMeR against pathologist ground truth MMR calls revealed AUROC of 0.98 (bootstrap 95% CI = 0.97–0.99) and Youden index (sensitivity plus specificity) of 1.87 at cutpoint of 10.7% MMR positive cells. This cutpoint gave positive predictive value (PPV) of >95% for both the commonest pattern of somatic MMRd (MLH1 and PMS2 loss) and for MMR proficient (MMRp) status, and agreement with pathologist calls approaching that between individual pathologists (k = 0.79–0.82 vs 0.88). Analysis of CRC recurrence-free interval (RFI) confirmed MMRd prognostic value in oxaliplatin-treated patients (multivariable-adjusted HR (aHR) = 0.62, 95% CI = 0.44–0.88, P=0.007), with effect size larger in those <70 years and those with right-sided tumours. MMRd did not predict differential benefit from chemotherapy duration. Patients with MMRp tumors had similar RFI whether treated with CAPOX or FOLFOX (aHR = 0.95, 95% CI= 0.77-1.16, P=0.6), while those with MMRd tumours treated with FOLFOX had shorter RFI (aHR = 2.08, 95% CI= 1.09-3.97, P=0.027, P INTERACTION=0.04).
Conclusions
AIMMeR holds promise to reduce pathologist workflow and streamline clinical diagnostics in CRC. The possible predictive value of MMRd for chemotherapy regimen should be investigated in additional cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D.N. Church.
Funding
Cancer Research UK, National Institute for Health Research (NIHR), Promedica.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Artificial intelligence-powered analysis of tumor lymphocytes infiltration: A translational analysis of AtezoTRIBE trial
Presenter: Martina Carullo
Session: Poster session 10
572P - Neoantigen heterogeneity among subtypes in colorectal cancer
Presenter: Fuqiang Li
Session: Poster session 10
574P - Comparative analysis of the tumor immune microenvironment (TIME) in primary and metastatic sites of microsatellite stable (MSS) and microsatellite instability-high (MSI) colorectal cancer
Presenter: Marwan Fakih
Session: Poster session 10
575P - Impact of immunological alterations and post-operative biomarkers on long-term outcomes in patients with locally advanced rectal cancer: Results from the STAR-01 study cohort
Presenter: Francesca Negri
Session: Poster session 10
576P - Prognostic values of a modified diagnostic biopsy-adapted immunoscore based on double immunohistochemical staining in patients with locally advanced rectal cancer
Presenter: Qiang Zeng
Session: Poster session 10
577P - Systematically assessing the intratissue microbiota in 937 patients with colorectal cancer
Presenter: Huanzi Zhong
Session: Poster session 10
578P - Tissue-resident microbiota characterization in colorectal cancer metastases
Presenter: Philippe Stevens
Session: Poster session 10
579P - A clinico-imaging predictive artificial intelligence model of relapse in colon cancer using baseline CT scans
Presenter: América Bueno Gómez
Session: Poster session 10
580P - Prognosis in stage II colorectal cancer: The effect of the primary tumor location and biomarkers
Presenter: Vincent Liégeois
Session: Poster session 10